百令胶囊联合布地奈德治疗小儿支气管哮喘疗效观察及对血清sFas、sFasL的影响  

Clinical Observation of Bailing Capsule Combined with Budesonide for Bronchial Asthma in Children and Its Effect on Serum sFas and sFasL

作　　者：吴宗跃[1] 王书举[1] 白婷 WU Zongyue;WANG Shuju;BAI Ting

机构地区：[1]河南省南阳市中心医院儿科,河南南阳473000

出　　处：《新中医》2020年第3期106-109,共4页New Chinese Medicine

摘　　要：目的:探讨百令胶囊联合布地奈德治疗小儿支气管哮喘的临床疗效,及其对血清可溶性凋亡相关因子(sFas)、可溶性凋亡相关因子配体(sFasL)的影响。方法:将小儿支气管哮喘患者80例随机分为对照组和治疗组,每组40例;2组患者均给予吸氧、抗炎、祛痰等常规治疗,对照组加用氢化可的松静脉滴注;治疗组加用百令胶囊口服及布地奈德雾化吸入,2组疗程均为1周;观察比较2组临床症状、体征消失时间及临床疗效,肺功能[第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1占预计值的百分比(FEV1%)]变化及不良反应,并检测治疗前后血清sFas、sFasL水平。结果:总有效率治疗组为85.0%,对照组为70.0%,2组比较,差异有统计学意义(P<0.05)。治疗后,治疗组患者喘憋、咳嗽缓解时间,肺部湿啰音、哮鸣音消失时间均短于对照组,差异有统计学意义(P<0.05)。治疗后,2组患者FEV1、FVC水平均较治疗前下降(P<0.05),FEV1%较治疗前升高(P<0.05);且治疗组各项指标改善较对照组更显著(P<0.05)。2组血清sFas、sFasL水平均较治疗前下降(P<0.05),且治疗组两项指标均低于对照组(P<0.05)。不良反应发生率治疗组为5.0%,对照组为10.0%,2组比较,差异无统计学意义(P> 0.05)。结论:百令胶囊联合布地奈德治疗小儿支气管哮喘疗效显著,可有效降低血清sFas、sFasL水平,改善患儿肺功能,且安全性较好。Objective:To discuss the clinical effect of Bailing capsule combined with budesonide for bronchial asthma in children,and its effect on soluble factor-related apoptosis(sFas) and soluble factor-related apoptosis ligand(sFasL) in serum.Methods: Divided 80 cases of patients with bronchial asthma in children into the control group and the treatment group randomly,40 cases in each group. Both groups received such routine treatments as oxygen inhalation,anti-inflammation and expelling phlegm;the control group additionally received hydrocortisone via intravenous drip,while the treatment group received Bailing capsule via oral administrationcombined with budesonide via aerosol inhalation. Th course of treatment of both groups lasted for one week. Observed and compared the clinical symptoms, the disappearance time of physical signs,clinical effect,changes of pulmonary functions [ forced expiratory volume in one second(FEV1), forced vital capacity(FVC),the percentage of FEV1 to its expected value(FEV1%)] and adverse reactions in both groups,and detected the levels of serum sFas and sFasL before and after treatment. Results:The total effective rate was 85.0% in the treatment group and 70.0% in the control group, difference being significant(P<0.05). After treatment, the relief time of asthmatic suffocating and coughing and the disappearance time of pulmonary moist rales and wheezing rales in the treatment group were respectively shorter than those in the control group,difference being significant(P<0.05). After treatment,the levels of FEV1 and FVC in both groups were lower than those before treatment(P<0.05),and FEV1% was higher than that before treatment(P<0.05);each index above in the treatment group was improved better than that in the control group(P<0.05). The levels of serum sFas and sFasL in both groups were lower than those before treatment(P<0.05), and the two indexes above in the treatment group were lower than those in the control group(P<0.05). The incidence of adverse reactions was 5.0% and 10.0% in the contro

关 键 词：小儿支气管哮喘 百令胶囊 布地奈德 SFAS SFASL 

分 类 号：R725.6[医药卫生—儿科]